ArticleFrontiers in oncology2022
Radiomic and Dosiomic Features for the Prediction of Radiation Pneumonitis Across Esophageal Cancer and Lung Cancer.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment.Radiation oncology (London, England) · 2022Trial
- Improving the Prediction of Radiation Pneumonitis: Leveraging Radiomics and Dosiomics Within IDLSS Lung Subregions.Life (Basel, Switzerland) · 2026Article
- Adapting federated radiomics models for radiation pneumonitis prediction in patients receiving thoracic radiotherapy with immunotherapy.Frontiers in immunology · 2026Article
- Radiomics and Deep Learning Prediction of Immunotherapy-Induced Pneumonitis From Computed Tomography.JCO clinical cancer informatics · 2025Article
- Predicting radiation pneumonitis with dose-segmented radiomics in locally advanced non- small cell lung cancer patients undergoing consolidative immunotherapy post- concurrent chemoradiotherapy.Frontiers in immunology · 2025Article
- Radiation pneumonitis prediction with dual-radiomics for esophageal cancer underwent radiotherapy.Radiation oncology (London, England) · 2024Article
- Establishing a 4D-CT lung function related volumetric dose model to reduce radiation pneumonia.Scientific reports · 2024Article
- A dosiomics model for prediction of radiation-induced acute skin toxicity in breast cancer patients: machine learning-based study for a closed bore linac.European journal of medical research · 2024Article
- Combining dosiomics and machine learning methods for predicting severe cardiac diseases in childhood cancer survivors: the French Childhood Cancer Survivor Study.Frontiers in oncology · 2024Article
- Stability of dosiomic features against variations in dose calculation: An analysis based on a cohort of prostate external beam radiotherapy patients.Journal of applied clinical medical physics · 2023Article
- Dosiomics and radiomics to predict pneumonitis after thoracic stereotactic body radiotherapy and immune checkpoint inhibition.Frontiers in oncology · 2023Article
- Article
- Function-Wise Dual-Omics analysis for radiation pneumonitis prediction in lung cancer patients.Frontiers in pharmacology · 2022Article
- Region-specific Multi-Omics Modeling for Predicting Acute Radiation-Induced Proctitis in Cervical Cancer Radiotherapy: A Retrospective Analysis.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim was to investigate the advantages of dosiomic and radiomic features over traditional dose-volume histogram (DVH) features for predicting the development of radiation pneumonitis (RP), to validate the generalizability of dosiomic and radiomic features by using features selected from an esophageal cancer dataset and to use these features with a lung cancer dataset. MATERIALS AND
methodsA dataset containing 101 patients with esophageal cancer and 93 patients with lung cancer was included in this study. DVH and dosiomic features were extracted from 3D dose distributions. Radiomic features were extracted from pretreatment CT images. Feature selection was performed using only the esophageal cancer dataset. Four predictive models for RP (DVH, dosiomic, radiomic and dosiomic + radiomic models) were compared on the esophageal cancer dataset. We further used a lung cancer dataset for the external validation of the selected dosiomic and radiomic features from the esophageal cancer dataset. The performance of the predictive models was evaluated by the area under the curve (AUC) of the receiver operating characteristic curve (ROCAUC) and the AUC of the precision recall curve (PRAUC) metrics.
resultThe ROCAUCs and PRAUCs of the DVH, dosiomic, radiomic and dosiomic + radiomic models on esophageal cancer dataset were 0.67 ± 0.11 and 0.75 ± 0.10, 0.71 ± 0.10 and 0.77 ± 0.09, 0.71 ± 0.11 and 0.79 ± 0.09, and 0.75 ± 0.10 and 0.81 ± 0.09, respectively. The predictive performance of the dosiomic- and radiomic-based models was significantly higher than that of the DVH-based model with respect to esophageal cancer. The ROCAUCs and PRAUCs of the DVH, dosiomic, radiomic and dosiomic + radiomic models on the lung cancer dataset were 0.64 ± 0.18 and 0.37 ± 0.20, 0.67 ± 0.17 and 0.37 ± 0.20, 0.67 ± 0.16 and 0.45 ± 0.23, and 0.68 ± 0.16 and 0.44 ± 0.22, respectively. On the lung cancer dataset, the predictive performance of the radiomic and dosiomic + radiomic models was significantly higher than that of the DVH-based model. However, the PRAUC of the dosiomic-based model showed no significant difference relative to the corresponding RP prediction performance on the lung cancer dataset.
conclusionThe results suggested that dosiomic and CT radiomic features could improve RP prediction in thoracic radiotherapy. Dosiomic and radiomic feature knowledge might be transferrable from esophageal cancer to lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.